The Predicted Potential of Quantitative T Cell Repertoire(TCR) Analysis Using Next-generation Sequencing (NGS) in Anti-PD-L1 Treatment in Non Small Cell Lung（NSCLC) Cancer Patients

First Affiliated Hospital of Zhejiang University1 site in 1 country10 target enrollmentMarch 1, 2017

ConditionsNon-Small Cell Lung Cancer

InterventionsAtezolizumab (MPDL3280A)

DrugsAtezolizumab (MPDL3280A)

Overview

Phase: Not Applicable
Intervention: Atezolizumab (MPDL3280A)
Conditions: Non-Small Cell Lung Cancer
Sponsor: First Affiliated Hospital of Zhejiang University
Enrollment: 10
Locations: 1
Primary Endpoint: T cell repertoire
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab in participants with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen. Treatment may continue until disease progression or unacceptable toxicity.

Registry

clinicaltrials.gov

Start Date

March 1, 2017

End Date

December 1, 2018

Last Updated

8 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

First Affiliated Hospital of Zhejiang University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Histologically documented, locally advanced or metastatic NSCLC
•Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens available or at least 12 unstained, freshly cut serial sections with associated pathology report that are evaluable for PD-L1 expression and epidermal growth factor receptor (EGFR) mutation status prior to enrollment, except for known sensitizing EGFR mutations in which case 10 unstained slides are required and there is no need for central testing of EGFR mutation status
•Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable, inoperable, or metastatic NSCLC, or disease recurrence within 6 months of treatment with a platinum-based adjuvant and/or neoadjuvant regimen or combined modality with curative intent
•Measurable disease per RECIST Version 1.1
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
•Life expectancy greater than or equal to (\>/=) 12 weeks
•Adequate hematologic and end organ function
•Agreement to remain abstinent or use contraceptive methods among women of childbearing potential or male partners of women of childbearing potential
•Recovery from all acute toxicities from previous therapy

Exclusion Criteria

•Active or untreated central nervous system (CNS) metastases
•Spinal cord compression not definitively treated or not clinically stable
•Leptomeningeal disease
•Uncontrolled pleural or pericardial effusions or ascites requiring recurrent drainage
•Uncontrolled tumor-related pain
•Uncontrolled hypercalcemia
•Malignancies other than NSCLC within 5 years prior to randomization, except for those curatively treated with negligible risk of metastasis or death
•Pregnant or lactating women
•Significant cardiovascular, pulmonary, or autoimmune disease
•Severe infection or major surgery within 4 weeks, or antibiotic treatment within 2 weeks prior to randomization

Arms & Interventions

Atezolizumab (MPDL3280)

Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.

Intervention: Atezolizumab (MPDL3280A)